RAC Clinical Trials and GCP Questions and Answers 1 — Questions and Answers
Question 1: An Institutional Review Board (IRB) is reviewing a protocol for a Phase 3 clinical trial. According to ICH GCP, which of the following is the PRIMARY responsibility of the IRB?
- Ensuring the scientific validity and statistical robustness of the trial design.
- Verifying the accuracy of the data collected at the clinical sites.
- Protecting the rights, safety, and well-being of the human subjects participating in the trial. (Correct answer)
- Confirming the sponsor has adequate financial resources to complete the study.
Correct answer: Protecting the rights, safety, and well-being of the human subjects participating in the trial.
The fundamental purpose of an IRB is to protect the rights and welfare of human research subjects. While scientific design is reviewed to assess the risk/benefit ratio, the IRB's primary mandate is the ethical oversight and protection of participants, not statistical validation, data verification, or financial auditing.
Question 2: A clinical trial investigator at a site becomes aware of a serious adverse event (SAE) that is both unexpected and fatal. According to FDA regulations (21 CFR 312.32), what is the sponsor's reporting obligation to the FDA?
- The sponsor must report the event to the FDA within 30 calendar days.
- The sponsor must report the event to the FDA as soon as possible, but no later than 15 calendar days after initial receipt of the information.
- The sponsor is only required to report the event in the annual safety report.
- The sponsor must report the fatal, unexpected suspected adverse reaction to the FDA as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information. (Correct answer)
Correct answer: The sponsor must report the fatal, unexpected suspected adverse reaction to the FDA as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information.
FDA regulations require expedited reporting for serious and unexpected suspected adverse reactions. For events that are fatal or life-threatening, the sponsor must notify the FDA within 7 calendar days. The 15-day timeline applies to other serious, unexpected suspected adverse reactions.
Question 3: Which of the following documents is considered an "Essential Document" that must be maintained at the investigator site BEFORE the clinical phase of a trial commences, according to ICH E6?
- The final clinical study report.
- Signed subject informed consent forms.
- The Investigator's Brochure. (Correct answer)
- All serious adverse event reports.
Correct answer: The Investigator's Brochure.
ICH E6 Section 8 divides essential documents into three phases: before, during, and after the trial. The Investigator's Brochure, which contains a summary of the clinical and nonclinical data on the investigational product, must be on file at the investigator site before the trial begins to inform the investigator and staff.
Question 4: During a monitoring visit, a Clinical Research Associate (CRA) compares the data entered into the electronic Case Report Forms (eCRFs) with the original medical records and lab results. This process is known as:
- Source Data Verification (SDV) (Correct answer)
- Informed Consent Review
- Protocol Amendment Submission
- Adverse Event Adjudication
Correct answer: Source Data Verification (SDV)
Source Data Verification (SDV) is the process of checking the data transcribed into the Case Report Forms (CRFs) against the original source documents to ensure the data is accurate, complete, and verifiable.
Question 5: A sponsor delegates the responsibility for clinical trial monitoring to a Contract Research Organization (CRO). Under ICH GCP guidelines, who holds the ultimate responsibility for the quality and integrity of the trial data?
- The CRO, because they are contracted to perform the monitoring.
- The Principal Investigator at each clinical site.
- The Sponsor, as they cannot delegate ultimate responsibility. (Correct answer)
- The Institutional Review Board (IRB) that approved the study.
Correct answer: The Sponsor, as they cannot delegate ultimate responsibility.
According to ICH GCP, while a sponsor may transfer trial-related duties and functions to a CRO, the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The sponsor must ensure oversight of any delegated functions.
Question 6: According to 21 CFR 50.25, which of the following is a required basic element of informed consent?
- A detailed biography of the principal investigator.
- A statement that participation is voluntary and the subject may discontinue participation at any time without penalty. (Correct answer)
- The complete financial disclosure of the study sponsor.
- A guarantee that the subject will receive personal benefit from participating in the research.
Correct answer: A statement that participation is voluntary and the subject may discontinue participation at any time without penalty.
The regulations in 21 CFR 50.25 list the basic elements that must be included in an informed consent document. A key element is the statement that participation is voluntary and that the subject can withdraw at any time without penalty or loss of benefits to which they are otherwise entitled.
RAC Clinical Trials and GCP Questions and Answers 1
An Institutional Review Board (IRB) is reviewing a protocol for a Phase 3 clinical trial.
According to ICH GCP, which of the following is the PRIMARY responsibility of the IRB?